NRXS
NeurAxis, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.96
−1.81%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.3M | 3.6M | 2.7M | 2.5M | 2.7M |
| Cost of Revenue | 767.7K | 562.9K | 362.0K | 303.3K | 297.1K |
| Gross Profit | 4.5M | 3.0M | 2.3M | 2.2M | 2.4M |
| Operating Expenses | |||||
| R&D Expense | 748.6K | 493.6K | 206.1K | 169.3K | 225.6K |
| SG&A Expense | 11.5M | 10.3M | 9.3M | 8.7M | 5.5M |
| General & Admin Expense | 7.8M | 8.1M | 8.9M | 8.3M | 5.1M |
| Selling & Marketing Expense | 3.7M | 2.3M | 324.7K | 323.6K | 410.9K |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 12.2M | 10.8M | 9.5M | 8.8M | 5.8M |
| Cost and Expenses | 13.0M | 11.4M | 9.8M | 9.1M | 6.1M |
| Operating Income (EBIT) | (7.7M) | (7.8M) | (7.2M) | (6.7M) | (3.4M) |
| Non-Operating | |||||
| Interest Income | — | — | — | (2.8K) | (2.3M) |
| Interest Expense | 51.9K | 74.0K | 300.7K | 5.4M | 417.6K |
| Net Interest Income | (51.9K) | (74.0K) | (300.7K) | (5.4M) | (2.7M) |
| Other Non-Op Income/Expense | 3.7K | 29.4K | (1.1M) | (8.0M) | (1.4M) |
| Non-Operating Income (excl Interest) | (108.0K) | (103.3K) | 784.0K | 2.6M | 990.2K |
| EBT (Pre-Tax Income) | (7.7M) | (7.8M) | (8.2M) | (14.6M) | (4.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (7.9M) | (7.8M) | (8.2M) | (14.6M) | (4.8M) |
| Earnings from Cont. Ops | (7.7M) | (7.8M) | (8.2M) | (14.6M) | (4.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.6M) | (7.8M) | (8.5M) | (14.6M) | (5.5M) |
| Per Share | |||||
| Basic EPS | ($0.77) | ($0.95) | ($1.22) | ($2.32) | ($0.57) |
| Diluted EPS | ($0.77) | ($0.95) | ($1.22) | ($2.32) | ($0.78) |
| Revenue Per Share | $0.44 | $0.39 | $0.39 | $0.39 | $0.32 |
| Shares | |||||
| Basic Shares Outstanding | 12.1M | 9.1M | 6.9M | 6.3M | 8.4M |
| Diluted Shares Outstanding | 12.1M | 9.1M | 6.9M | 6.3M | 8.4M |
| Profitability Metrics | |||||
| EBITDA | (7.5M) | (7.7M) | (7.9M) | (9.2M) | (4.3M) |
| D&A | 73.2K | 59.5K | 37.8K | 40.7K | 37.1K |
| EBIT | (7.6M) | (7.7M) | (7.9M) | (9.3M) | (4.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026